Androgen deprivation therapy (ADT) involves the use of antiandrogens which act as competitive inhibitors for androgen receptors, effectively blocking the androgen-signaling axis critical for prostate cancer cell survival and proliferation [16]. The gene discussed is AR; the disease is prostate cancer.